CN108348603B - 抗cd3叶酸结合物和其用途 - Google Patents

抗cd3叶酸结合物和其用途 Download PDF

Info

Publication number
CN108348603B
CN108348603B CN201680064414.8A CN201680064414A CN108348603B CN 108348603 B CN108348603 B CN 108348603B CN 201680064414 A CN201680064414 A CN 201680064414A CN 108348603 B CN108348603 B CN 108348603B
Authority
CN
China
Prior art keywords
antibody
amino acid
antibodies
naturally encoded
encoded amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680064414.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108348603A (zh
Inventor
拉希德·哈伦
田方
马可·吉姆诺波罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrx Inc
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of CN108348603A publication Critical patent/CN108348603A/zh
Application granted granted Critical
Publication of CN108348603B publication Critical patent/CN108348603B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201680064414.8A 2015-11-03 2016-11-02 抗cd3叶酸结合物和其用途 Active CN108348603B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250451P 2015-11-03 2015-11-03
US62/250,451 2015-11-03
US201562267086P 2015-12-14 2015-12-14
US62/267,086 2015-12-14
US201662374693P 2016-08-12 2016-08-12
US62/374,693 2016-08-12
PCT/US2016/060087 WO2017079272A2 (en) 2015-11-03 2016-11-02 Anti-cd3-folate conjugates and their uses

Publications (2)

Publication Number Publication Date
CN108348603A CN108348603A (zh) 2018-07-31
CN108348603B true CN108348603B (zh) 2023-12-29

Family

ID=58662682

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680064414.8A Active CN108348603B (zh) 2015-11-03 2016-11-02 抗cd3叶酸结合物和其用途

Country Status (13)

Country Link
US (2) US11851488B2 (enExample)
EP (1) EP3370771A4 (enExample)
JP (2) JP6931649B2 (enExample)
KR (1) KR20180077271A (enExample)
CN (1) CN108348603B (enExample)
AU (1) AU2016349786C1 (enExample)
BR (1) BR112018009004A8 (enExample)
CA (1) CA3002573A1 (enExample)
IL (1) IL258759B2 (enExample)
MX (1) MX2018005232A (enExample)
NZ (1) NZ743049A (enExample)
SG (2) SG10201913746RA (enExample)
WO (1) WO2017079272A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200126360A (ko) * 2017-11-22 2020-11-06 젤터, 인코포레이티드 콜라겐을 조작하기 위한 방법 및 시스템
CA3110647A1 (en) * 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
KR102239781B1 (ko) 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
WO2020232165A1 (en) * 2019-05-14 2020-11-19 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
BR112021023048A2 (pt) 2019-05-21 2022-04-19 Novartis Ag Moléculas de ligação a cd19 e usos das mesmas
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊（中國）有限公司 抗cd3抗體葉酸生物共軛物及其用途
CA3187085A1 (en) 2020-08-25 2022-03-03 Manuel Baca Multi-specific antigen binding molecules targeting hiv and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102618605A (zh) * 2003-06-18 2012-08-01 斯克利普斯研究院 非天然活性氨基酸遗传密码增加
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
CN103289960B (zh) 2003-04-17 2017-04-26 斯克利普斯研究院 扩展真核生物遗传密码
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
DK2794658T3 (en) 2011-12-19 2017-06-19 Synimmune Gmbh BISPECIFIC ANTIBODY MOLECULE
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
MX2016000272A (es) 2013-07-12 2016-08-03 Zymeworks Inc Construcciones de unión a los antígenos cd19 y cd3 biespecificos.
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3371220A2 (en) * 2015-11-02 2018-09-12 Janssen Pharmaceutica NV Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
KR20200143730A (ko) * 2018-04-17 2020-12-24 인벤라 인코포레이티드 3가 삼중 특이성 항체 구조물
CA3110647A1 (en) * 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
US20220226488A1 (en) * 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
KR20210142638A (ko) * 2019-02-22 2021-11-25 우한 이지 바이오파마 씨오., 엘티디. Cd3 항원 결합 단편 및 이의 응용

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102618605A (zh) * 2003-06-18 2012-08-01 斯克利普斯研究院 非天然活性氨基酸遗传密码增加
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Recruiting cytotoxic T cells to folate-receptor-positive cancer cells;Sumith A. Kularatne等;《Angewandte Chemie(International ed. in English) 》;20130925;第46卷(第52期);摘要、第3页、第5页第2段、补充材料 *

Also Published As

Publication number Publication date
IL258759B2 (en) 2023-04-01
SG10201913746RA (en) 2020-03-30
AU2016349786C1 (en) 2024-11-07
MX2018005232A (es) 2018-08-15
IL258759B (en) 2022-12-01
US20180319885A1 (en) 2018-11-08
AU2016349786B2 (en) 2023-11-16
JP7220755B2 (ja) 2023-02-10
US20240239889A1 (en) 2024-07-18
WO2017079272A2 (en) 2017-05-11
JP6931649B2 (ja) 2021-09-08
NZ743049A (en) 2025-08-29
EP3370771A4 (en) 2019-06-19
IL258759A (en) 2018-06-28
JP2021181487A (ja) 2021-11-25
CN108348603A (zh) 2018-07-31
SG11201803211TA (en) 2018-05-30
JP2018535972A (ja) 2018-12-06
BR112018009004A8 (pt) 2019-02-26
CA3002573A1 (en) 2017-05-11
WO2017079272A9 (en) 2017-08-03
US11851488B2 (en) 2023-12-26
BR112018009004A2 (pt) 2018-10-30
KR20180077271A (ko) 2018-07-06
AU2016349786A1 (en) 2018-06-21
EP3370771A2 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
CN108348603B (zh) 抗cd3叶酸结合物和其用途
EP2970478B1 (en) Cd20-binding immunotoxins for inducing cellular internalization and methods using same
US12377294B2 (en) Anti-CD3 antibody folate bioconjugates and their uses
CN114450022A (zh) 分离部分及其使用方法
CN113840832A (zh) 可活化白介素-2多肽及其使用方法
CN112654635A (zh) 可活化细胞因子多肽及其使用方法
EP3702367A1 (en) Novel pd-l1 binding polypeptides for imaging
KR20160062761A (ko) 키메라 항원 수용체 t 세포 스위치 및 이의 용도
JP2019505172A (ja) 非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
EP4132581A1 (en) HUMANIZED ANTIBODY TARGETING THE TUMOR ASSOCIATED ANTIGEN IL13Ra2
CN113226357A (zh) 双特异性缀合物
JP2025066806A (ja) 癌のためのフィブロネクチンエクストラドメインｂ（ｅｄｂ）特異性ｃ－ｔ
CN116763937A (zh) 抗人pd-l1和tlr7双靶向纳米抗体偶联药物及其在抗肿瘤中的应用
WO2021173889A1 (en) Uses of anti-cd3 antibody folate bioconjugates
TWI827807B (zh) 抗cd3抗體葉酸生物共軛物及其用途
HK40023815A (en) Anti-cd3 antibody folate bioconjugates and their uses
Nadal Isolation and validation of novel monoclonal antibodies targeting the tumor microenvironment for the selective delivery of cytokines payloads
TW202544032A (zh) Ｈｅｒ２特異性抗原結合蛋白與細胞素之偶聯物
KR20240149030A (ko) 항-bcam 항체 및 항체-약물 접합체
WO2025098446A1 (zh) 抗bcma单域抗体及其应用
HK1199043A1 (en) Targeted interferon demonstrates potent apoptotic and anti-tumor activities

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant